- Report
- October 2023
- 140 Pages
Global
From €3275EUR$3,599USD£2,808GBP
- Report
- April 2024
- 198 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- April 2024
- 104 Pages
Europe
From €1365EUR$1,500USD£1,170GBP
- Report
- April 2024
- 96 Pages
North America
From €1365EUR$1,500USD£1,170GBP
- Report
- April 2024
- 104 Pages
Asia Pacific
From €1365EUR$1,500USD£1,170GBP
- Report
- April 2024
- 104 Pages
Middle East, Africa
From €1365EUR$1,500USD£1,170GBP
- Report
- February 2022
- 602 Pages
Europe
From €8186EUR$8,995USD£7,018GBP
- Report
- November 2019
China
From €7276EUR$7,995USD£6,238GBP
- Book
- May 2019
- 896 Pages
- Book
- September 2018
- 616 Pages
- Book
- November 2013
- 320 Pages
- Book
- February 2018
North America
- Book
- December 2015
- 4176 Pages

Benign Prostatic Hyperplasia (BPH) is a common condition in men over the age of 50, where the prostate gland enlarges and causes urinary symptoms. It is a major concern in Urology and Nephrology, as it can lead to complications such as urinary retention, bladder stones, and even kidney failure. Treatment options for BPH include lifestyle changes, medications, and minimally invasive procedures.
The BPH market is composed of a variety of products and services, including medications, medical devices, and surgical procedures. Medications used to treat BPH include alpha-blockers, 5-alpha reductase inhibitors, and anticholinergics. Medical devices used to treat BPH include transurethral resection of the prostate (TURP) and transurethral microwave thermotherapy (TUMT). Surgical procedures used to treat BPH include open prostatectomy and laparoscopic prostatectomy.
Some companies in the BPH market include Allergan, Boston Scientific, Medtronic, and Urovant Sciences. Show Less Read more